Inventor · disambiguated record
Karthik Viswanathan
Also filed as: VISWANATHAN KARTHIK
40 granted patents·33 pending applications·212 citations·filing 2005–2025
97Inventor score
Files withVISTERRA INC50MASSACHUSETTS INST TECHNOLOGY11SASISEKHARAN RAM3BOSQUES CARLOS2BETENBAUGH MICHAEL J1
Top patents by PatentIndex Score
73 records- 0197US11136385B2Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody moleculeVISTERRA INC·Filed 2020·Granted Oct 5, 2021·4 cites·38 claims
- 0297US10954296B2Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGAVISTERRA INC·Filed 2020·Granted Mar 23, 2021·4 cites·51 claims
- 0397US9212217B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Dec 15, 2015·14 cites·21 claims
- 0496US10968270B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 6, 2021·3 cites·30 claims
- 0596US9365639B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2015·Granted Jun 14, 2016·9 cites·30 claims
- 0694US8209132B2Methods and products related to the improved analysis of carbohydratesBOSQUES CARLOS·Filed 2009·Granted Jun 26, 2012·55 cites·14 claims
- 0793US10385123B2Antibody molecules to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2018·Granted Aug 20, 2019·8 cites·30 claims
- 0893US8877200B2HA binding agentsVISTERRA INC·Filed 2013·Granted Nov 4, 2014·17 cites·9 claims
- 0992US10800835B2HA binding agentsVISTERRA INC·Filed 2018·Granted Oct 13, 2020·4 cites·20 claims
- 1092US10155806B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2016·Granted Dec 18, 2018·4 cites·30 claims
- 1192US9096657B2HA binding agentsVISTERRA INC·Filed 2014·Granted Aug 4, 2015·13 cites·30 claims
- 1291US9709567B2Compositions and methods for diagnosing and/or treating influenza infectionMASSACHUSETTS INST TECHNOLOGY·Filed 2016·Granted Jul 18, 2017·6 cites·5 claims
- 1391US2025066464A1Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2024·Application pending·0 cites
- 1489US11912781B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2022·Granted Feb 27, 2024·1 cites·10 claims
- 1589US2024425569A1Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 1688US11059883B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2018·Granted Jul 13, 2021·2 cites·30 claims
- 1788US10513553B2Compositions and methods for treating and preventing influenzaVISTERRA INC·Filed 2016·Granted Dec 24, 2019·6 cites·22 claims
- 1888US9745352B2Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccinesMASSACHUSETTS INST TECHNOLOGY·Filed 2014·Granted Aug 29, 2017·5 cites·6 claims
- 1988US9572861B2Engineered polypeptide agents for targeted broad spectrum influenza neutralizationMASSACHUSETTS INST TECHNOLOGY·Filed 2016·Granted Feb 21, 2017·6 cites·11 claims
- 2087US10981982B2Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2020·Granted Apr 20, 2021·1 cites·48 claims
- 2187US9969794B2HA binding agentsVISTERRA INC·Filed 2013·Granted May 15, 2018·7 cites·50 claims
- 2287US8637456B2Engineered polypeptide agents for targeted broad spectrum influenza neutralizationSASISEKHARAN RAM·Filed 2011·Granted Jan 28, 2014·11 cites·8 claims
- 2386US12264203B2Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Apr 1, 2025·0 cites·13 claims
- 2485US9334309B2Engineered polypeptide agents for targeted broad spectrum influenza neutralizationMASSACHUSETTS INST TECHNOLOGY·Filed 2014·Granted May 10, 2016·6 cites·15 claims
- 2584US12227587B2Humanized complement 5A receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2024·Granted Feb 18, 2025·0 cites·10 claims
- 2683US12415865B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Sep 16, 2025·0 cites·2 claims
- 2783US12187807B2Antibody molecules to C5AR1 and uses thereofVISTERRA INC·Filed 2023·Granted Jan 7, 2025·0 cites·4 claims
- 2883US11168131B2Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2016·Granted Nov 9, 2021·4 cites·15 claims
- 2983US9278998B2Compositions and methods for diagnosing and/or treating influenza infectionJAYARAMAN AKILA·Filed 2010·Granted Mar 8, 2016·7 cites·12 claims
- 3083US8802110B2Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccinesRAMAN RAHUL·Filed 2011·Granted Aug 12, 2014·7 cites·46 claims
- 3180US12091451B2Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)VISTERRA INC·Filed 2021·Granted Sep 17, 2024·0 cites·18 claims
- 3278US12054539B2Antibody molecules to dengue virus and uses thereofVISTERRA INC·Filed 2021·Granted Aug 6, 2024·0 cites·20 claims
- 3376US11945868B2Antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2018·Granted Apr 2, 2024·1 cites·37 claims
- 3476US2025296982A1Engineered polypeptides and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 3575US10226527B2Hemagglutinin polypeptides, and reagents and methods relating theretoTHARAKARAMAN KANNAN·Filed 2011·Granted Mar 12, 2019·4 cites·12 claims
- 3674US12024552B2Ha binding agentsVISTERRA INC·Filed 2020·Granted Jul 2, 2024·0 cites·19 claims
- 3774US2025043014A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 3873US9408890B2Multivalent liposome formulationsCHARLES STARK DRAPER LABORATORY INC·Filed 2014·Granted Aug 9, 2016·1 cites·17 claims
- 3973US8815522B2Decoy influenza therapiesSASISEKHARAN RAM·Filed 2009·Granted Aug 26, 2014·2 cites·36 claims
- 4073US2024301065A1Antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 4171US11773179B2Antibody molecules to C5aR1 and uses thereofVISTERRA INC·Filed 2021·Granted Oct 3, 2023·0 cites·4 claims
- 4271US2023365694A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2022·Application pending·0 cites
- 4371US2025171555A1Humanized complement 5a receptor 1 antibodies and methods of use thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 4471US2024342300A1Antibody molecule-drug conjugates and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 4570US2024092921A1Antibody molecules to april and uses thereofVISTERRA INC·Filed 2023·Application pending·0 cites
- 4670US2019330326A1Antibody molecules to a proliferation-inducing ligand (april)VISTERRA INC·Filed 2019·Application pending·0 cites
- 4769US2024383958A1Apelin receptor agonists and uses thereofVISTERRA INC·Filed 2024·Application pending·0 cites
- 4867US2025382379A1Humanized antibody molecules to cd138 and uses thereofVISTERRA INC·Filed 2025·Application pending·0 cites
- 4966US2023416372A1IMMUNOSILENCING Fc VARIANTSVISTERRA INC·Filed 2023·Application pending·0 cites
- 5064US12338291B2Humanized antibody molecules to CD138 and uses thereofVISTERRA INC·Filed 2020·Granted Jun 24, 2025·0 cites·21 claims
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Karthik Viswanathan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →